DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of August 2018 for DBV Technologies S.A., a clinical-stage biopharmaceutical company headquartered in Montrouge, France, with additional offices in New York, NY. The company develops Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform designed to treat food allergies and other immune diseases. Its primary product candidates include Viaskin Peanut, Viaskin Milk, and Viaskin Egg.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding investor relations activities and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on upcoming corporate events.
Guidance, Outlook, and Management Commentary
Management has announced a schedule of investor presentations and meetings for September 2018:
- September 6, 2018: Charles Ruban (COO) will host meetings at Citi's 13th Annual Biotech Conference in Boston, MA.
- September 7, 2018: David Schilansky (Deputy CEO) will host meetings at the Goldman Sachs Biotech Symposium in London, UK.
- September 13, 2018: Kevin Trapp (CCO) and Susanna Mesa (CBO) will present at the Morgan Stanley 16th Annual Global Healthcare Conference in New York, NY. A live webcast and replay will be available on the company's website.
The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the specific dates and times of the September 2018 investor conference presentations.
- Confirm the availability of the live webcast and replay for the Morgan Stanley conference on the company's investor relations website.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains none.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk, which are central to the company's current business model.